34,000-patient study finds weight loss injections like Ozempic reduce cancer risk by 20% over 15 years, with similar impacts as bariatric surgery.
Weight loss injections like Ozempic have shown potential in reducing cancer risk by 20% over 15 years, according to a study involving 34,000 patients. The drugs, which also reverse diabetes and lower heart attack and stroke risks, belong to the GLP-1 receptor agonist class and were discussed at the American Society of Clinical Oncology's annual meeting. Researchers found that patients taking these drugs were 19% less likely to develop cancer over 15 years, with similar impacts on cancer risk as bariatric surgery.
June 04, 2024
8 Articles